drugset / Trial / NCT02461186
Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar
Phase 2/3
Withdrawn
University of Oxford
Department of Medical Research, Lower Myanmar · collabMahidol Oxford Tropical Medicine Research Unit · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Emerging resistance to artemisinins and their partner drugs severely threatens the treatment of falciparum malaria in Myanmar with artemisinin combination therapies. To inform drug policy, it is crucial to evaluate alternative antimalarial treatments. The investigators here propose a randomized clinical trial comparing parasite clearance parameters and efficacy of 3 days arterolane-piperaquine with standard treatment with 3 days dihydroartemisinin (DHA)-piperaquine in adult patients with uncomplicated falciparum malaria in Myanmar stratified for the presence of "K13" mutation in the infecting parasite strains.
Timeline
- Start
- 2015-06
- Primary completion
- 2017-06
- Completion
- 2017-06
Outcome
Outcome not reported
Stopped: “Change of the study site due to the current political climate in Myanmar.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARTENIMOL | Small molecule | — | — |
| Subject | Arterolane | Small molecule | — | — |
| Subject | piperaquine | Small molecule | — | — |